GSK adds to its trove of positive data for multiple myeloma contender as rivals continue to command the spotlight

GlaxoSmithKline’s cancer R&D team put up more positive numbers for its ADC belantamab mafodotin, one of its top pipeline prospects.

Flashing the results just ahead of a busy ASCO weekend, Axel Hoos and the team noted new multiple myeloma data highlighting promising responses from their open-label DREAMM-6 study — after confirming the overall response rate of 32% among heavily pre-treated patients reviewed in DREAMM-2.